HAWK Biosystems’ Post

In this episode of the Life Science Success Podcast, 🌟 Meet Thomas Rademacher, MD, PhD: A Trailblazer in the Intersection of Science and Entrepreneurship 🌟 Pioneering Leadership: As the co-founder and CEO of Emergex, Dr. Rademacher exemplifies the fusion of deep scientific knowledge with visionary leadership, steering the company towards innovative healthcare solutions. Academic Excellence: With a rich academic background, including an Emeritus Professorship of Molecular Medicine at the University College of London, his journey from hardcore biochemistry PhD studies at the University of Wisconsin Madison has set a solid foundation for his groundbreaking work. Innovation in Monoclonal Antibodies: Dr. Rademacher's significant contributions to monoclonal antibody research, particularly using Chinese hamster ovary (CHO) cells, have paved the way for advancements in modern medicine and biotechnology. Entrepreneurial Spirit: His entrepreneurial ventures, notably including the Glycobiology Institute, highlight his ability to translate scientific research into successful business endeavors, attracting interest from major corporations. Forward-Thinking in Immunology and Vaccinology: Currently focused on developing next-generation vaccines that activate the cellular immune response, Dr. Rademacher's work involves cutting-edge technologies like quantum-confined gold clusters and micro-needle delivery systems. Dr. Thomas Rademacher embodies the spirit of innovation, seamlessly blending research and entrepreneurship to tackle some of the most pressing challenges in healthcare today. Follow his journey as he continues to make significant strides in science and industry. #HealthcareInnovation #Biotechnology #Leadership #MonoclonalAntibodies #Vaccinology https://lnkd.in/gCfaMrFB

Great seminar for celebrating 20 years Sygnature: To celebrate sygnature's 20 years successful business, the company organized a series of events across the global sites, including the seminar series showcasing by the client companies a number of successful fully integrated projects carried out at Sygnature Discovery. I can say confidently on behalf of everyone who attended the seminar really enjoyed the excellent presentations of candidates development and clinical progress. There are a few points left me with strong impression: 1. Novel target selection based on human genetics for related diseases is likely yielding a successful clinical product. 2. Importance of establishing biomarkers for clinical candidates. 3. having a quality lead molecule through various screening technologies will lead to quality candidates as there is usually non significant structural change of clinical molecules from the leads. 4. excellent cooperative working relationships between Sygnature teams and clients. 5. perseverance in tackling scientific challenges. 6. comprehensive capability and service offering and scientific expertise across all disciplines at one site are really advantageous for candidate development. All in all, though nothing above is new , but good to see these are reflected in real case studies. Very happy to see all the client companies are very happy with the products developed at Sygnature which no doubt make scientists involved in these projects very proud of their achievement. Many thanks for Dr Brett Stevenson who organized this series of event by getting the client companies around the world contributing to the event.

📢 Join Our Upcoming Webinar! 🚀 🔬 Titre : New Advances in Extracellular Vesicle miRNA Research Using High-Throughput Affinity Capture 🗓️ When: Wednesday, February 28th at 20:00 🔍 About: 🔍Extracellular vesicles (EVs) are a diverse group of membrane-bound particles ranging from approximately 30nm up to a few micrometers in diameter. The development of accurate and reliable EV-based diagnostics necessitates the identification of disease-associated biomarkers within specific EV subpopulations and the implementation of rapid, reproducible and scalable sample processing. Conventional isolation methods face challenges due to the co-isolation of particles with similar physicochemical properties. Promising alternatives involve methods targeting specific vesicle-surface epitopes, compatible with automated platforms. Join our featured speaker, Dr. Greg Rice from INOVIQ, as he identifies challenges associated with translating our understanding of extracellular vesicle biology into clinically useful applications and to highlight potential solutions. 🎙️ Présenté par :Dr. Greg Rice, INOVIQ 👉 Inscrivez-vous maintenant afin de le visionner à la demande https://lnkd.in/g-8PMzze

AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.     Our #InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest. We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF). Ahead of Rare Disease Day this Thursday, please join the Oxford-Harrington 2024 Rare Disease Day Webinar hosted on Wednesday, Feb. 28, 2024, from 10:00 – 11:00 a.m. EST/3:00 p.m. to 4:00 p.m. GMT by clicking the link below. @HarringtonDI_UH @OHRareDisease

We are thrilled to announce that Dr. Brian Coblitz, Executive Director of the Technology Commercialization Office at The George Washington University, will be a distinguished panelist on May 19, 2024, at the upcoming American Society for Pharmacology and Experimental Therapeutics - ASPET 2024 conference.   Title: Moving Your Discovery From Bench to Bedside: IP Considerations for Scientists   This essential session will delve into the successful translation of biomedical discoveries, focusing on commercial products, and highlighting the critical role of intellectual property (IP) protection. It is designed for both early-career and established scientists interested in novel therapeutic targets and commercialization.   Dr. Coblitz will assemble with an in-depth panel discussion alongside other esteemed experts from government, industry, and academia. The panel, co-chaired by Diane E. Peters of John Hopkins Medicine and Tara Kirby of the NIH Office of Technology Transfer, will explore key IP concepts and discuss the nuanced challenges of IP protection in translational drug discovery.   Join us to gain invaluable insights into navigating the complexities of technology transfer and IP strategy in the biomedical field.   For more information: https://lnkd.in/emK9drHc   #ASPET2024 #BiomedicalResearch #IntellectualProperty #TechnologyTransfer #Innovation #GWU    

More roles of MIF need exploring

The ALTTO and NeoALTTO trials – together involving more than 8,000 patients and establishing a huge prospective collection of biological materials for translational research – are a testimony to the strength and richness in terms of scientific expertise, creativity, and flexibility of BIG’s network of research groups to conduct complex international clinical studies. They were coordinated by BIG, the Institut Jules Bordet – Clinical Trials Support Unit, Frontier Science Scotland, and SOLTI in collaboration with GSK and Novartis. Learn more on this BIG achievement here 👉 https://lnkd.in/eYgndBF5 #BIGagainstbc #breastcancer #Breastcancerresearch

What prompted me to go through this "lecture" few rounds? Sharing this for a better outreach - with our young chemistry and chemical biology / life sciences generation (in the India context). Making science matter: A vision for a new century of life-changing science Peter Schultz, PhD, President & CEO, Scripps Research (January 10, 2024) https://lnkd.in/gHpjByvi (directly taken from the website: https://lnkd.in/ggxJdFzC) ABOUT THE LECTURE In 2024, Scripps Research is celebrating a century of scientific discovery and innovative medicines..... TOP TAKEAWAY POINTS 1. Over the last century, Scripps Research has made tremendous scientific strides in everything from revealing the secrets of our sensory and immune systems to creating new technologies to accelerate the discovery of life-saving medicines. The Institute now houses six research departments, multiple Nobel laureates and a top-ranked graduate school. 2. Scripps Research sets the standard for excellence in a number of research fields, evidenced by the steady stream of groundbreaking discoveries that emerge from the Institute’s labs in chemistry, neuroscience, integrative structural and computational biology, molecular medicine, and immunology and microbiology, to name a few. Scripps Research discoveries have enabled 15 FDA-approved medicines. 3. Despite the remarkable advances in our understanding of human biology and disease, there is still an overwhelming need for new medicines, including for viral diseases, cancer and degenerative diseases of aging. One of the main barriers is that scientific discoveries and new insights into disease processes continue to be primarily made in academic research centers, while drug discovery and development are carried out in the biopharmaceutical industry. 4. To overcome these hurdles, Schultz is creating unique translational capabilities at Scripps Research in the form of the Calibr-Skaggs Institute for Innovative Medicines and the Scripps Research Translational Institute that seamlessly turn new discoveries into innovative, new medicines and clinical advances that impact human health. Already, Calibr-Skaggs has entered nine medicines into clinical trials, with many more in the pipeline. 5. As Scripps Research enters a new century, the Institute is pioneering the development of a new vision for research institutes which transcends conventional boundaries that constrain the impact on science, medicine and the public. This will help enable exceptional scientists to perform transformative research, while accelerating the advancement of new medicines for people around the world.

Follow us and our Cluster member Miltenyi Biotec on the exciting journey from target validation via proof of principle in small scale to clinical scale: In three hybrid sessions and a hands-on demo day on the CliniMACS Prodigy we will focus on different stages of the development of cell- and genetherapies in our seminar series “From target validation to clinical application”. As an expert in the field,Miltenyi Biotec will help you set up your own experiments with exclusive tips and tricks based on more than 10 years of experience. In our first seminar we will talk about the potential of Spatial Biology for target identification and validation as well as possibilities for patient stratification using the MACSima Platform. Our second and third seminar will focus on how to translate a cellular therapy approach from the early benchtop experiments to a clinical scale production. 

February 14th, love is in the air, and our hearts are racing with happiness to share about one of BIOCONNECT project partners, the Latvian Institute of Organic Synthesis (LIOS), leading the charge in cardiovascular research alongside their focus on cancer, infectious diseases, and central nervous system disorders. 💊 Explore the realm of advanced drug discovery with LIOS, whose extensive track record speaks volumes: * 18 original medicines introduced; * > 100 generic medicines launched; * 70 papers published annually. 🧬 From Horizon projects to expertise in organic synthesis, computational modeling, and more, they're at the forefront of innovation. 🌟 LIOS proudly stands as the highest-rated research organization in Latvia, earning top honors in the international evaluation of scientific institutions conducted in 2020. 💡 Their commitment to interdisciplinary collaboration and progression within the life sciences domain drives scholarly advancement, influencing the trajectory of medical research and related fields. Moreover, their substantial contributions to the 𝐁𝐈𝐎𝐂𝐎𝐍𝐍𝐄𝐂𝐓 project underscore their indispensable function in fostering development and innovative initiatives. #BIOCONNECT #BIOCONNECTproject #LIOS #collaboration #support #lifesciences #connection #science #research #connection #innovation